Regulatory of Personalized medicine

The FDA is  already started to take initiatives to integrate personalized medicine into their regulatory policies.They developed a report in October 2013 entitled Paving the Way for Personalized Medicine FDAs role in a New Era of Medical Product Development in which they outlined steps they would have to take to integrate genetic and biomarker information for clinical use and drug development. They determined that they would have to develop specific regulatory science standards, research methods, reference material and other tools in order to incorporate personalized medicine into their current regulatory practices. For example, they are working on a genomic reference library for regulatory agencies to compare and test the validity of different sequencing platforms in an effort to uphold reliability.

  • FDA and Personalized medicine
  • Regulatory aspects of pharmacogenetics
  • FDA and predictive medicine
  • FDA and validation of biomarkers

Related Conference of Regulatory of Personalized medicine

May 9-10, 2019

17th European Pathology Congress

| Amsterdam, Netherlands
June 28-29, 2019

Breast Pathology and Cancer

Oslo, Norway
July 31 - August 1, 2019

International Conference on Surgical Pathology

Amsterdam,Netherlands
July 31- August 01, 2019

International Conference on Molecular Pathology

Amsterdam | Netherlands
August 21-22, 2019

17th Asia Pacific Pathology Congress

Singapore
November 08-09, 2019

18th Global Congress on Pathology

| San Francisco | United States
November 13-14, 2019

World Congress on Histopathology

Tokyo, Japan
November 25-26, 2019

2nd European Pathology and Infectious Disease Conference

Helsinki, Finland
December 09-10, 2019

14th International Conference on Laboratory Medicine & Pathology

Kuala Lumpur, Malaysia

Regulatory of Personalized medicine Conference Speakers

Recommended Sessions

Related Journals

Are you interested in